PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Tilray Brands, Inc. (TLRY.TO)
2.000.05 (2.56%)
1.90 - 2.15
0.48 - 2.54
9.88M / 2.92M (Avg.)
-0.48 | -4.19
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
3.38%
Revenue growth under 50% of CRON.TO's 18.36%. Michael Burry would suspect a deteriorating sales pipeline or weaker brand.
44.31%
Gross profit growth similar to CRON.TO's 48.26%. Walter Schloss would assume both firms track common industry trends.
143.07%
EBIT growth 1.25-1.5x CRON.TO's 128.35%. Bruce Berkowitz would verify if strategic initiatives are driving this edge.
143.07%
Operating income growth under 50% of CRON.TO's 632.73%. Michael Burry would be concerned about deeper cost or sales issues.
-154.14%
Negative net income growth while CRON.TO stands at 85.00%. Joel Greenblatt would push for a reevaluation of cost or revenue strategies.
-148.34%
Negative EPS growth while CRON.TO is at 23.46%. Joel Greenblatt would expect urgent managerial action on costs or revenue drivers.
-145.86%
Negative diluted EPS growth while CRON.TO is at 23.46%. Joel Greenblatt would require immediate efforts to restrain share issuance or boost net income.
23.88%
Share count expansion well above CRON.TO's 16.41%. Michael Burry would question if management is raising capital unnecessarily or is over-incentivizing employees with stock.
23.19%
Diluted share count expanding well above CRON.TO's 9.38%. Michael Burry would fear significant dilution to existing owners' stakes.
No Data
No Data available this quarter, please select a different quarter.
-100.98%
Both companies show negative OCF growth. Martin Whitman would analyze broader economic or industry conditions limiting cash flow.
-48.44%
Both companies show negative FCF growth. Martin Whitman would consider an industry-wide capital spending surge or margin compression.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
82.29%
Positive long-term OCF/share growth while CRON.TO is negative. John Neff would see a structural advantage in sustained cash generation.
82.29%
Positive OCF/share growth while CRON.TO is negative. John Neff might see a comparative advantage in operational cash viability.
87.74%
Positive 3Y OCF/share CAGR while CRON.TO is negative. John Neff might see a big short-term edge in operational efficiency.
-240.94%
Both face negative decade-long net income/share CAGR. Martin Whitman would suspect a shrinking or highly disrupted sector.
-240.94%
Both exhibit negative net income/share growth over five years. Martin Whitman would suspect a challenging environment for the entire niche.
6.64%
Positive short-term CAGR while CRON.TO is negative. John Neff would see a clear advantage in near-term profit trajectory.
1674.77%
10Y equity/share CAGR above 1.5x CRON.TO's 121.02%. David Dodd would confirm if consistent earnings retention or fewer write-downs drive this advantage.
1674.77%
5Y equity/share CAGR above 1.5x CRON.TO's 121.02%. David Dodd might see stronger earnings retention or fewer asset impairments fueling growth.
3789.23%
3Y equity/share CAGR above 1.5x CRON.TO's 121.02%. David Dodd verifies the company’s short-term capital management far exceeds the competitor’s pace.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
57.85%
AR growth is negative/stable vs. CRON.TO's 185.07%, indicating tighter credit discipline. David Dodd confirms it doesn't hamper actual sales.
43.35%
Inventory growth well above CRON.TO's 57.35%. Michael Burry suspects overshooting production or weaker sell-through vs. the competitor.
52.48%
Asset growth above 1.5x CRON.TO's 25.50%. David Dodd checks if M&A or new capacity expansions are value-accretive vs. competitor's approach.
14.24%
BV/share growth above 1.5x CRON.TO's 8.40%. David Dodd confirms if consistent profit retention or fewer write-downs yield faster equity creation.
272.38%
We have some new debt while CRON.TO reduces theirs. John Neff sees the competitor as more cautious unless our expansions pay off strongly.
-50.01%
Our R&D shrinks while CRON.TO invests at 0.00%. Joel Greenblatt checks if we risk falling behind a competitor’s new product pipeline.
-24.57%
We cut SG&A while CRON.TO invests at 64.47%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.